Shots:

• The approval is based on P-III KEYNOTE-189 trial assessing Keytruda + pemetrexed & Pt CT in patients with 1L metastatic non-sq NSCLC- with no EGFR or ALK genomic tumor aberrations regardless of PD-L1 tumor expression status
• The P-III KEYNOTE-189 trial resulted in improvement in OS- reduction in the risk of death by half- improvement in PFS
• Keytruda (pembrolizumab) 100mg is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2 and is evaluated in 900 trial globally in oncology

Ref: Merck & Co. | Image: Merck